Skip to content

Released Nov 9, 2026, before the open

10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-071873

Q3 2026 · 10-Q
Revenue$83.54M+924.7% vs Q3 2025+419.8% vs Q2 2026
Net Income$58.15MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted$0.80N/M vs Q3 2025N/M vs Q2 2026
Operating Income$56,639,000N/M
Operating Cash Flowderived-$18,243,000N/M
Free Cash Flowderived-$18,250,000N/M
Margins · derived
Operating margin67.8%+294.7 pt vs Q3 2025
Net margin69.6%+264.0 pt vs Q3 2025

What the release said

Net income was $58.2 million for the three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025.

Collaboration revenue was $83.5 million for the three months ended September 30, 2026, compared to $8.2 million, driven by a $74.1 million cumulative catch-up adjustment.2

Net income was $58.2 million for the three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025.1

Research and development expenses were $18.8 million and general and administrative expenses were $5.8 million for the three months ended September 30, 2026.34

As of September 30, 2026, the Company had $156.2 million in cash, cash equivalents, and marketable securities, providing cash runway into the second half of 2029.5

Dose-range finding studies for the oral I&I program are expected to begin in the fourth quarter of 2026, with potential first-in-human studies by the end of 2027.6

Collaboration revenue
$83.5 million Three months ended September 30, 2026, compared to $8.2 million for the three months ended September 30, 20252
Net income
$58.2 million Three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 20251
Research and development expenses
$18.8 million Three months ended September 30, 2026, compared to $20.0 million for the three months ended September 30, 20253
General and administrative expenses
$5.8 million Three months ended September 30, 2026, compared to $6.7 million for the three months ended September 30, 20254
Cash, cash equivalents, and marketable securities
$156.2 million As of September 30, 20265
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$83.54M$8.15M$7.81M$17.48M
Net Income$58.15M-$15.85M-$19.12M-$14.35M
EPS Diluted$0.80-$0.25-$0.31-$0.34

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR